⚫ Hucke, F., Sieghart, W., Pinter, M., Graziadei, I., Vogel, W., Müller, C., Heinzl, H., Waneck, F., Trauner, M., Peck-Radosavljevic, M.:

The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE

Journal of Hepatology 2014;60: 118 – 126

⚫ Sieghart W. Pinter M. Hucke F. Graziadei I. Schoniger-Hekele M. Muller C. Vogel W. Trauner M. Peck-Radosavljevic M.

Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.

Hepatology. 57(6):2224-34, 2013 Jun.

⚫ Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M.

The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.

⚫ Wenjun Li, Florence Fenollar, Jean-Marc Rolain,Pierre-Edouard Fournier, Gerhard E. Feurle, Christian Müller,Verena Moos, Thomas Marth, Martin Altwegg,Romana C. Calligaris-Maibach, Thomas Schneider, Federico Biagi, Bernard La Scola and Didier Raoult

Genotyping reveals a wide heterogeneity of Tropheryma whipplei.

Microbiology 2008; 154: 521–527      

⚫ F. Biagi, C. Badulli, G. E Feurle, Ch. Müller, V. Moos, Th. Schneider, Th. Marth, J. Mytilineos, F. Garlaschelli, A. Marchese, L.Trotta, P. I. Bianchi, M. Di Stefano, A. L. Cremaschi, A. De Silvestri, L. Salvaneschi, M. Martinetti, G. R Corazza.

Cytokine genetic profile in Whipple’s disease.

European Journal of Clinical Microbiology & Infectious Diseases 2012; 31:3145-3150

⚫ M. Pinter, F. Hucke, I. Graziadei, W. Vogel, A. Maieron, R. Königsberg, R. Stauber,  B. Grünberger, Ch. Müller, C. Kölblinger, M. Peck-Radosavljevic, W. Sieghart

Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib.

Radiology 2012; 263:590-99

⚫ W. Sieghart, M. Pinter, M. Reisegger, Ch.Müller, A. Ba-Ssalamah, J.Lammer, M.Peck-Radosavljevic

Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.

European Radiology 2012; 22: 1214-1223

⚫ M. Pinter, W. Sieghart, F. Hucke, I. Graziadei, W. Vogel, A. Maieron, R. Königsberg, A. Weissmann, G. Kornek, J. Matejka, R. Stauber, R. Buder, B. Grünberger, M. Schöniger-Hekele, C. Müller, M. Peck-Radosavljevic

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

Aliment Pharmacol Ther. 2011;34(8):949-59

⚫ J. Lammer,K Malagari,T.Vogl, F. Pilleul, A. Denys, A. Watkinson, M. Pitton, G. Sergent, T.Pfammatter, S.Terraz, Y. Benhamou, Y. Avajon, T. Gruenberger, M. Pomoni, H. Langenberger, M. Schuchmann, J. Dumortier, Ch. Mueller, P.Chevallier, R. Lencioni, On Behalf of the PRECISION V Investigators.

Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma:

Results of the PRECISION V Study

Cardiovasc Intervent Radiol (2010) 33:41–52

⚫ Dolak, W. Leitner, J. Maresch, J. Wrba, F. Mueller, C.

In vivo identification by confocal laser endoscopy of foamy macrophages associated with Whipple's disease.

Endoscopy. 2010;42: Suppl 2:E310-1

⚫ M.Schöniger-Hekele, J.Kettenbach, M.Peck-Radosavljevic, Ch.Müller:

Octreotide treatment of patients with hepatocellular carcinoma – a retrospective single center controlled study.

J.Exp.and Clin.Cancer Research 2009; 28: 142

⚫ M.Martinetti, F.Biagi, C.Badulli, G.E.Feurle, Ch.Müller, V.Moos, Th.Schneider, Th.Marth, A.Marchese, L.Trotta, S.Sachetto, A.Pasi, A.De Silvestri, L.Salvaneschi, G.R.Corazza:

The HLA Alleles DRB1*13 and DQB1*06 are associated to Whipple’s disease.

Gastroenterology 2009; 136:2289-2294

⚫ Ch.Müller, M.Schöniger-Hekele, R.Schernthaner, B.Renner, M.Peck-Radosavljevic, A.Brichta, M.Posch, P.Bauer, P.Ferenci, A.Gangl

Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial.

Wien Klin Wochenschr 2008; 120: 608-618

⚫ Pinter M., Wichlas M., Schmid K., Plank Ch., Müller Ch., Wrba F., Peck-Radosavljevic M.

Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.

⚫ M. Blum, Ch.Müller, M.Peck-Radosavljevic, Wrba F., Berlakovich G., Mühlbacher F., Steininger R., Speiser M., Pones M., Hüpfl M., Lammer J., Kettenbach J.

MR-guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplanation.

Minimally invasive therapy 2007; 4: 230-240.

⚫ L.Jessner, T.Watkins-Riedel, Ch.Müller, E.Formann, M.Gschwantler, P.Ferenci:

Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV monitor, version 2.0, assays in HCV genotype 4 infection.

J.of Viral Virology 2007

⚫ L. Dzirlo, M.Hubner, Ch. Müller, B. Blaha, E. Formann, Ch. Dellinger, P. Petzelbauer, L. Müllauer, K. Huber, M. Kneussl, M. Gschwantler

Sarcoidosis-like lesions of the lung and the skin

Lancet 2007; 369: 1832

⚫ M.Schöniger-Hekele, Ch.Müller, L.Kramer, E.Dauber, W.R.Mayr, F.Wrba, S.Rockenschaub, F.Mühlbacher:

Graft versus host disease after orthotopic liver transplantation documented by analysis of short tandem repeat polymorphisms

Digestion 2006; 74: 169-173

⚫ M.Schöniger-Hekele, D.Petermann, B.Weber, Ch.Müller:

Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers.

Applied and Environmental Microbiology 2007; 73

⚫ V.Fuhrmann, Ch.Madl, Ch.Müller, U.Holzinger, R.Kitzberger, G-Ch.Funk, P.Schenk:

Hepatopulmonary syndrome in patients with hypoxic hepatitis.

Gastroenterology 2006; 131: 69-75.

⚫ M. Schöniger-Hekele, S.Hänel, F.Wrba, Ch.Müller:

Hepatocellular carcinoma – survival and clinical characteristics in relation to various histologic molecular markers in Western patients.

Liver Int 2005; 25: 62-69

⚫ M. Schöniger-Hekele, Ch.Müller:

The combined elevation of tumor markers CA 19.9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Dig.Dis.Sci. 2006; 51: 338-345

⚫ T.Watkins-Riedel, P.Ferenci, P.Steindl-Munda, M.Gschwantler, Ch.Müller, M.Wögerbauer:

Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCVRNA whole-blood analysis.

Clinical Infectious Diseases 2004; 39: 1754-1760

⚫ P.Schenk, M.Schöniger-Hekele, V.Fuhrmann, Ch.Madl, G Silberhumer, Ch.Müller:

Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Gastroenterology 2003; 125: 1042-1052